NEW YORK, May 3 (GenomeWeb News) - Qiagen said today that it has acquired the worldwide exclusive rights and licenses to manufacture and market all of RNAture's nucleic acid isolation products from its parent company,
Pursuant to the companies' agreement, Hitachi Chemical Research will transfer all current commercial operations to Qiagen. Additional terms were not disclosed. Qiagen said it does not expect the transaction to have a material impact on its financial outlook for 2005.
According to Qiagen, RNAture's product portfolio focuses on mRNA isolation products and comprises solutions for the capture of cellular poly(A)+ RNA in the wells of specially treated microplates, and includes products marketed under the GenePlate name.